Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
about
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemiaBmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentPharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisAurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Selection of therapy: rational decisions based on molecular events.Treatment options for chronic myeloid leukemia.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Omacetaxine mepesuccinate in chronic myeloid leukemia.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia.Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia.T315I, more or less, predicts for major molecular response: the devil is in the details!Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia.Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight.Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia.
P2860
Q33402841-B93DC5B8-532A-4009-84CB-78AC77C8EE53Q33886011-D96F862A-67C2-494E-A2CB-2C973885162DQ34743455-0529619D-F514-4E42-BDDA-DBECCDD77991Q34976801-2759F447-2A81-478E-BB8F-283011F35BFEQ35669231-54C67953-CE12-4F45-AD46-8AB2A7CB99DEQ35967452-1E2924FA-8EF6-41F8-921D-C32260C9C96EQ36130255-BE902E1A-9587-40C1-BF0A-491B9A10BFB6Q36141909-2BAF988A-B7B4-4334-8A32-09DA497350B0Q36324767-E0E2F2C4-16E6-41AE-A114-D8C65804E795Q36800451-A859E1BF-80D2-4A0B-BF80-DA2F46FF7D8BQ37027753-AE91D7B9-8D35-4CBA-BA00-CE8D5AF50382Q37102026-D2BA6B49-F260-4A5B-AF9C-378BE1954316Q37212678-53006E1A-99DC-410F-B5AB-EF89223988D5Q37690579-DEF7B5A1-16C2-42C1-88B4-A554E65E035DQ37809083-77A4F301-7F1B-421E-B6E0-54EE4919AA63Q37827278-2BB9C52B-988D-4A1F-8E1F-819C3D1D73DAQ37875969-B8F5BCAB-DF94-4B9E-BD89-BDD503157A64Q37952910-57C56C27-AABE-43D4-8195-D725A52BE3E8Q37994805-6EC3B47F-083D-4A63-9032-B4D5BBE190C0Q38023947-384324A0-1555-4D8E-A5D4-612F16D01CE2Q38207017-E8C160CF-116F-42DC-ADBE-C0E0D87C5378Q38258641-0E56039F-1746-4519-B97E-3CD19B390461Q39112294-B60CED83-2CAD-4DF7-B937-9A11C5D9AF2CQ39404871-CA0ADAE6-AF49-4078-AC44-283291620A9DQ39779762-741F191A-98E9-41B0-B2EE-63F4699B5556Q41539993-A2E72B49-045E-4871-8CFC-92FA2C5DE2E2Q41912896-B57436A9-FB5E-438C-988E-22AC17354079Q42145852-A6279B54-EB3F-4E4E-A74F-7D771AC2987BQ42153537-D6E25B2A-7226-4B3E-ADCE-1C5B93210805Q42533789-6E819804-FFB7-43E5-86CA-F91E86548938Q43181384-899F65DE-A7D5-400A-A7A0-6816150FA717Q46321468-71A3C67B-AAC7-4DBF-AEAB-A306B90AC2C4Q47858676-85FC2D76-F2ED-4E53-8C21-D51325F50FB2Q48168059-D9B4C7E9-3648-4CE9-B1CA-A9F4D68509A8Q50897874-A11DEB29-5CFC-4B08-85A5-5D4DDB7E34C2Q54273566-ED28A38B-64EB-4B3A-B323-883916A37906Q54326636-67B914E7-C7AB-41F8-978F-276395A3616AQ54498929-8BFF7178-656C-412D-9AF1-B0B4BEA018A2Q54533328-876D2740-CE02-4C3E-A531-9F4BAC335D9BQ55068793-3A8058AB-6A0A-4763-870A-47ADC9ACA23A
P2860
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epidemiologic study on survival of chronic myeloid leukemia and Ph
@nl
Epidemiologic study on surviva ...... s with BCR-ABL T315I mutation.
@en
type
label
Epidemiologic study on survival of chronic myeloid leukemia and Ph
@nl
Epidemiologic study on surviva ...... s with BCR-ABL T315I mutation.
@en
prefLabel
Epidemiologic study on survival of chronic myeloid leukemia and Ph
@nl
Epidemiologic study on surviva ...... s with BCR-ABL T315I mutation.
@en
P2093
P2860
P50
P1433
P1476
Epidemiologic study on surviva ...... s with BCR-ABL T315I mutation.
@en
P2093
Cesar Sanz Rodriguez
Charles Chuah
Dong-Wook Kim
Franck E Nicolini
Fumiharu Yagasaki
Inge H Dufva
Jane F Apperley
Jay D Pearson
John M Goldman
Martin C Müller
P2860
P304
P356
10.1182/BLOOD-2009-04-219410
P407
P50
P577
2009-10-20T00:00:00Z